Sky Labs Inc.
386380.KQ
KOSDAQ22,950.00
KRW
-1,000.00
- -
ISIN
KR7386380000
Return %
Stock
S&P500
1Y
-2.34
16.05
3Y
-2.34
77.49
5Y
-2.34
72.82
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Byunghwan Lee
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 703, C’s Tower, 58 Seongnam-si GY South Korea 13486
- IPO Date
- Sep 4, 2026
- Website
- skylabs.io
- Similar Companies
- Business
- Sky Labs Inc. develops and provides artificial intelligence-enabled digital healthcare solutions and wearable medical devices for chronic-disease monitoring, with a focus on generating clinically meaningful physiological data from everyday use. The Company’s principal offerings include CART BP pro, a ring-type, cuffless blood-pressure-monitoring medical device for healthcare professionals and outpatient management; CART BP, a consumer-oriented ring-type blood-pressure monitoring solution; CART-O, a solution for inpatient monitoring; and CART ON, a chronic-disease healthcare platform that collects, analyzes, supports diagnosis using, and distributes outpatient health data. Its products integrate photoplethysmography sensors, proprietary deep-learning algorithms, automatic long-term blood-pressure measurement capabilities, and smartphone, tablet and PC-based software platforms; CART BP pro provides 24-hour ambulatory blood-pressure-monitoring data and health evaluation metrics to support diagnosis and individualized treatment decisions. The Company is also developing multi-vital-sign and medical-data products, including CART O2 for oxygen-saturation measurement and CART Vital for integrated monitoring of blood pressure, pulse, respiratory rate, body temperature and oxygen saturation, and is extending its technology toward physiological biomarkers such as blood glucose and blood lipids. Sky Labs serves hospitals, clinics, healthcare professionals, chronic-disease patients, consumers, medical researchers and healthcare-platform partners in South Korea and international markets. Founded in 2015, the Company is headquartered in Seongnam-si, South Korea. Recent developments include the September 2026 listing of its shares on the KOSDAQ market; distribution agreements covering eight European countries and three South American countries; collaboration with Germany-based IEM to enter European hospital and clinic markets; preparation of clinical work for U.S. Food and Drug Administration authorization of CART BP pro; adoption of its clinical data platform by the Korea National Institute of Health; and inclusion of its cuffless blood-pressure monitoring technology in the Korean Society of Hypertension clinical practice guidelines. Sky Labs also secured a strategic investment from Omron Healthcare in 2025, established consumer-product distribution arrangements with Omron Healthcare and a hospital-product distribution agreement with Otsuka Pharmaceutical in Japan, and commercially launched CART ON following Korean Ministry of Food and Drug Safety approval.